The SmartCDK is a digital therapeutic under clinical development to treat patients with metastatic breast cancer. It is a custom app to monitor toxicity and side effects during treatments with CDK 4/6 inhibitors such as Palbociclib, Ribociclib and Abemaciclib with either Fulvestrant or an Aromatase inhibitor.
We believe, when our SmartCDK is used in combination with a CDK 4/6 inhibitor, it will improve patient’s Quality of Life and reduce healthcare costs. Once the clinical data is available, a new drug application would be filed with the FDA for approval as a prescription-only digital therapeutic.
The SmartI-O is a custom built digital therapeutic for checkpoint inhibitors.It can monitor unexpected and rate side effects assocaited with any of the five checkpoint inhibitors and their combinations.
Witty Health is developing blockchain technology enabled INCENTIVIZED VALUE BASED platform integrated with most commonly used cancer drugs. We believe it would help reduce preventable ER visits and Hospitalizations related costs.